share_log

Roth MKM Reiterates Buy on Panbela Therapeutics, Maintains $25 Price Target

Benzinga ·  Dec 18, 2023 10:41

Roth MKM analyst Jonathan Aschoff reiterates Panbela Therapeutics (NASDAQ:PBLA) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment